Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 valproic acid + bevacizumab + oxaliplatin/fluoropyrimidine in RAS-mutated metastatic colorectal cancer
2018-001414-15Phase 2Active
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of valproic acid in colorectal cancer (CRC) and rectal cancer (2 arms), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: PFS. Started Jan 2022; status: active.
02
Drugs
valproic acid
03
Conditions
colorectal cancer (CRC)rectal cancer
Beyond the preview
Go deeper on 2018-001414-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001414-15.